ONTX Stock Overview
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer.
Notes are coming soon
Onconova Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.87|
|52 Week High||US$2.06|
|52 Week Low||US$0.62|
|1 Month Change||36.69%|
|3 Month Change||20.43%|
|1 Year Change||-50.27%|
|3 Year Change||-83.08%|
|5 Year Change||-99.72%|
|Change since IPO||-100.00%|
Recent News & Updates
|ONTX||US Pharmaceuticals||US Market|
Return vs Industry: ONTX underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: ONTX underperformed the US Market which returned -8.5% over the past year.
|ONTX Average Weekly Movement||11.3%|
|Pharmaceuticals Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: ONTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: ONTX's weekly volatility (11%) has been stable over the past year.
About the Company
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19.
Onconova Therapeutics, Inc. Fundamentals Summary
|ONTX fundamental statistics|
Is ONTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ONTX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.83|
|Net Profit Margin||-7,658.41%|
How did ONTX perform over the long term?See historical performance and comparison